Recent evidence suggests a profibrotic role of the PD1/PD-L1 axis in IPF and mediastinal lymph nodes (30–32), paving the way for the therapeutic exploitation of low doses of immune checkpoint inhibitor (33, 34). Here, CD274 is linked to idiopathic pulmonary fibrosis.